Manager TitleAgeSince
President - 2025-07-29
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
+3.62%+1.68%+48.80%+98.41% 1,040B
+2.13%-1.76%+33.04%+61.88% 599B
+3.32%+4.47%+23.72%+91.59% 485B
+3.80%+3.21%+73.99%+41.69% 350B
+3.09%+3.03%+29.59%+45.42% 345B
+2.82%+2.20%+17.90%+40.15% 272B
+3.40%+0.99%-3.44%+12.08% 244B
+3.21%+3.15%+45.01%+49.99% 223B
+3.80%+4.56%+29.59%+97.73% 183B
Average +2.93%+1.90%+33.13%+59.88% 415.87B
Weighted average by Cap. +2.66%+1.53%+36.79%+68.68%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock